Humacyte $245 million richer after SPAC deal ahead of Nasdaq debut

27 August 2021

US biotech Humacyte has announced the successful completion of its business combination with Alpha Healthcare Acquisition Corp (AHAC), a special purpose acquisition company (SPAC) sponsored by Constellation Alpha Holdings.

The resulting combined company, Humacyte, is due to commence trading of its shares of common stock and warrants on the Nasdaq Global Select Market under the ticker symbols HUMA and HUMAW, on Friday.

"Humacyte is poised to make commercial-scale bioengineered tissues a reality for patients"Humacyte is developing universally implantable bioengineered human tissue at commercial scale. Its off-the-shelf human acellular vessels (HAVs) initially being developed for vascular repair, reconstruction and replacement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK